Biogen Idec Inc. has priced its new multiple-sclerosis pill at a discount to a competing therapy made by Novartis AG , a strategy that could speed up sales of the Biogen drug.
http://www.foxbusiness.com/news/2013/03/29/biogen-idec-prices-multiple-sclerosis-drug-below-oral-competitor/
http://www.foxbusiness.com/news/2013/03/29/biogen-idec-prices-multiple-sclerosis-drug-below-oral-competitor/
No comments:
Post a Comment